CR8220A - Composicion de fexofenadina y proceso para su preparacion - Google Patents

Composicion de fexofenadina y proceso para su preparacion

Info

Publication number
CR8220A
CR8220A CR8220A CR8220A CR8220A CR 8220 A CR8220 A CR 8220A CR 8220 A CR8220 A CR 8220A CR 8220 A CR8220 A CR 8220A CR 8220 A CR8220 A CR 8220A
Authority
CR
Costa Rica
Prior art keywords
fexofenadine
composition
preparation
excipients
filler
Prior art date
Application number
CR8220A
Other languages
English (en)
Inventor
Nandi Indranil
Anilbhai Patel Ashish
Sadatrezael Mohsen
Davila Pablo
Maheshappa Khanapure Virendra
Wasudeorao Durugkar Surendra
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of CR8220A publication Critical patent/CR8220A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se refiere a una composicion farmaceutica que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma, una celulosa de hidroxipropilo sustituida baja, un relleno, preferiblemente lactosa y opcionalmente otros excipientes.
CR8220A 2003-07-31 2006-01-30 Composicion de fexofenadina y proceso para su preparacion CR8220A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/631,874 US20050065183A1 (en) 2003-07-31 2003-07-31 Fexofenadine composition and process for preparing

Publications (1)

Publication Number Publication Date
CR8220A true CR8220A (es) 2006-07-27

Family

ID=34135544

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8220A CR8220A (es) 2003-07-31 2006-01-30 Composicion de fexofenadina y proceso para su preparacion

Country Status (12)

Country Link
US (1) US20050065183A1 (es)
EP (1) EP1651218A1 (es)
JP (1) JP2007500682A (es)
AR (1) AR045193A1 (es)
AU (1) AU2004262914A1 (es)
BR (1) BRPI0413186A (es)
CR (1) CR8220A (es)
EC (1) ECSP066327A (es)
NO (1) NO20060991L (es)
RU (1) RU2006105720A (es)
WO (1) WO2005013987A1 (es)
ZA (1) ZA200600519B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158334A0 (en) * 2001-04-09 2004-05-12 Teva Pharma Polymorphs of fexofenadine hydrochloride
AU2004312530A1 (en) 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
JP2007532687A (ja) * 2004-04-26 2007-11-15 テバ ファーマシューティカル インダストリーズ リミティド フェキソフェナジン塩酸塩の結晶形およびその製造方法
JP2008514641A (ja) * 2004-09-28 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド 結晶形フェキソフェナジン、およびその調製方法
US20070048373A1 (en) * 2005-08-30 2007-03-01 Cima Labs Inc. Dried milled granulate and methods
EP1808163A1 (en) * 2005-12-22 2007-07-18 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
CN101340896A (zh) * 2005-12-22 2009-01-07 特瓦制药工业有限公司 含有低溶解性药物的压缩的固体剂型和其制备方法
EP2037918A2 (en) * 2006-05-15 2009-03-25 Acadia Pharmaceuticals Inc. Pharmaceutical formulations of pimavanserin
RU2453315C2 (ru) * 2010-08-17 2012-06-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения аллергических заболеваний
CA2811634C (en) * 2010-09-21 2019-01-15 Intekrin Therapeutics, Inc. Antidiabetic solid pharmaceutical compositions
JP2013119540A (ja) * 2011-12-08 2013-06-17 Nipro Corp 固形医薬組成物およびその製造法
JP6040218B2 (ja) * 2012-02-23 2016-12-07 フロイント産業株式会社 口腔内崩壊錠用直打賦形剤及びその製造方法、並びに口腔内崩壊錠
JP6184727B2 (ja) * 2013-04-15 2017-08-23 ロート製薬株式会社 医薬組成物
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
CN106137989A (zh) * 2016-07-20 2016-11-23 南通雅本化学有限公司 一种基于盐酸非索非那定的药物组合物
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
JP6410895B2 (ja) * 2017-07-26 2018-10-24 ロート製薬株式会社 医薬組成物
JP2019011350A (ja) * 2018-09-25 2019-01-24 ロート製薬株式会社 医薬組成物
WO2022123511A1 (en) * 2020-12-11 2022-06-16 Cellix Bio Private Limited A composition comprising fexofenadine
GB2629127A (en) 2022-08-31 2024-10-23 Novumgen Ltd An orodispersible tablet of fexofenadine and its process of preparation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878217A (en) * 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
JPS52151717A (en) * 1976-06-09 1977-12-16 Shionogi & Co Ltd Sugar coating on solid preparations
US4285957A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
JPS6183123A (ja) * 1984-09-28 1986-04-26 Taisho Pharmaceut Co Ltd 抗喘息剤
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
CA2134211C (en) * 1992-05-11 1999-06-29 James K. Woodward Use of terfenadine derivatives as antihistaminics in a hepatically impaired patient
EP1369409B1 (en) * 1993-06-24 2006-04-05 AMR Technology, Inc. Process for preparing compounds useful as intermediates
DK0812195T3 (da) * 1995-02-28 2003-03-03 Aventis Pharma Inc Farmaceutisk sammensætning til piperidinoalkanolforbindelser
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
JPH09315971A (ja) * 1996-05-28 1997-12-09 Daito Kk テルフェナジン含有錠剤製剤
ATE503472T1 (de) * 1996-11-15 2011-04-15 Ajinomoto Kk Nateglinide-tablettenzubereitungen
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
AU2199500A (en) * 1998-12-23 2000-07-31 Alza Corporation Gastric retention dosage form having multiple layers
EP1054019A1 (en) * 1999-05-18 2000-11-22 Shin-Etsu Chemical Co., Ltd. Low-substituted hydroxypropyl cellulose
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6375982B1 (en) * 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine

Also Published As

Publication number Publication date
ZA200600519B (en) 2007-01-31
BRPI0413186A (pt) 2006-10-03
NO20060991L (no) 2006-04-28
WO2005013987A1 (en) 2005-02-17
EP1651218A1 (en) 2006-05-03
AU2004262914A1 (en) 2005-02-17
AR045193A1 (es) 2005-10-19
JP2007500682A (ja) 2007-01-18
RU2006105720A (ru) 2007-09-10
ECSP066327A (es) 2006-07-28
US20050065183A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
CR8220A (es) Composicion de fexofenadina y proceso para su preparacion
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
CR9363A (es) Composiciones para la transmision transmucosa oral de la metformina
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
DOP2006000170A (es) Nuevos derivados de espirocromanona
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
CL2007003209A1 (es) Composicion que comprende una vacuna de flavivirus vivos atenuados; composicion que comprende un producto farmaceutico derivado de virus o proteina; un metodo para la elaboracion de una composicion terapeutica que comprende liofilizar las composicion
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
AR052221A1 (es) Metodo para el tratamiento de la enfermedad poliquistosis renal
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
AR073265A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
AR054806A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
AR065342A1 (es) Composiciones farmaceuticas que contienen fumarato de quetiapina
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
AR032479A1 (es) Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina
CO6382170A2 (es) Composiciones farmacéuticas que comprenden 3-(1.h.-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]pirrol-2,5-diona o una sal farmacéuticamente aceptable del mismo y procesos para su producción.
CL2008001872A1 (es) Compuestos derivados de piperidincarboxamida sustituidas; proceso de preparación de estos; composición farmacéutica que los comprende; y usos en el tratamientos de la hipertensión, entre otras.
PT1490049E (pt) Citalopram para o tratamento da pre3ssao sanguinia elevada.
MX2025010595A (es) Composiciones y métodos para administrar paltusotina a pacientes con insuficencia hepática
EA200500957A1 (ru) Применение l-допа, его производных и лекарственных средств, содержащих эти соединения, для профилактики психотических заболеваний
ITMI20042187A1 (it) Derivati isossazolici per allievare il dolore neiropatico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)